

DEC 16 2002  
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner of Patents and Trademarks,  
Washington, D.C. 20231 on December 10, 2002.

David Saliwanchik  
David R. Saliwanchik, Patent Attorney

DT07 Rec'd PCT/PTO 16 DEC 2002

Patent Application  
Docket No. SPO-116  
Serial No. 10/070,569

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Takashi Muramatsu, Kohji Okamoto, Shinya Ikematsu, Munehiro Oda,  
Hideshi Kumai, Sadatoshi Sakuma  
Serial No. : 10/070,569  
Conf. No. : 7190  
Filed : March 8, 2002  
For : Early Cancer Tumor Marker

Office of Initial Patent Examination  
Customer Service Center  
Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RECEIVED  
JAN 21 2003  
TECH CENTER 1600/2900

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The applicants respectfully request the correction of an error in the official Filing Receipt for the above-identified patent application. The typographical error has occurred in spelling of the 6<sup>th</sup> inventors first name. The correction needed is as follows:

Applicant(s)

Sadotoshi Sakuma

should read

Sadatoshi Sakuma

A copy of the erroneous Official Filing Receipt accompanies this Request. Also, attached is a copy of page 1 of the Transmittal Letter Form PTO-1390 and a copy of the executed Declaration and Power of Attorney form. Correction of the above is respectfully requested.


Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Enclosures: Copy of erroneous Filing Receipt;  
Page 1 of Form PTO-1390;  
Copy of Declaration and Power of Attorney form.



**UNITED STATES  
PATENT AND  
TRADEMARK OFFICE**

 Commissioner for Patents  
 Washington, DC 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/070,569	07/16/2002	1632	594	SPO-116	12	9	5

23557

SALIWANCHIK LLOYD & SALIWANCHIK  
 A PROFESSIONAL ASSOCIATION  
 2421 N.W. 41ST STREET  
 SUITE A-1  
 GAINESVILLE, FL 326066669



CONFIRMATION NO. 7190

**FILING RECEIPT**

\*OC000000009072570\*

Date Mailed: 11/07/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Takashi Muramatsu, Aichi, JAPAN;  
 Kohji Okamoto, Fukuoka, JAPAN;  
 Shinya Ikematsu, Kanagawa, JAPAN;  
 Munehiro Oda, Kanagawa, JAPAN;  
 Hideshi Kumai, Kanagawa, JAPAN;  
 Sadotoshi Sakuma, Tokyo, JAPAN;

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/JP00/06147 09/08/2000

**Foreign Applications**

JAPAN 11-256678 09/10/1999  
 JAPAN 11-345404 12/03/1999  
 JAPAN 2000-033168 02/10/2000

**Projected Publication Date:** None, application is not eligible for pre-grant publication

**Non-Publication Request:** No

**Early Publication Request:** No

**RECEIVED**  
 JAN 21 2003  
 TECH CENTER 1600/2900

**Title**

Early cancer tumor marker

**Preliminary Class**

435

**LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PCT

COPIES  
DEC 16 2002  
PATENT & TRADEMARK OFFICE

FORM PTO-1390  
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

SPO-116

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

INTERNATIONAL APPLICATION NO.

PCT/JP00/06147

INTERNATIONAL FILING DATE

08 September 2000

PRIORITY DATE CLAIMED

10 September 1999

TITLE OF INVENTION

EARLY CANCER TUMOR MARKER

APPLICANT(S) FOR DO/EO/US

Takashi Muramatsu, Kohji Okamoto, Shinya Ikematsu, Munehiro Oda, Hideshi Kumai, Sadatoshi Sakuma

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) unsigned.
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: Certificate of Mailing by Express Mail